PTGX FY 2020 Earnings — Protagonist Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

PTGXProtagonist Therapeutics, Inc.

$6B

FY 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$29M+12293.1% YoY

Gross Profit

$29M100.0% margin

Operating Income

-$65M-225.4% margin

Net Income

-$66M-231.1% margin

EPS (Diluted)

$-1.92

Cash Flow

Operating Cash Flow

-$72M

Free Cash Flow

-$73M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$324M

Total Liabilities

$45M

Stockholders' Equity

$280M

Cash & Equivalents

$117M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$29M	$231,000	+12293.1%
Gross Profit	$29M	$231,000	+12293.1%
Operating Income	-$65M	-$81M	+19.9%
Net Income	-$66M	-$77M	+14.3%